176 related articles for article (PubMed ID: 1375284)
1. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
Hainsworth JD; Johnson DH; Greco FA
J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
[TBL] [Abstract][Full Text] [Related]
2. The role of cisplatin/bleomycin-based chemotherapy in the treatment of poorly differentiated carcinoma of unknown primary site.
Hainsworth JD; Johnson DH; Greco FA
Semin Oncol; 1992 Apr; 19(2 Suppl 5):54-7; discussion 58. PubMed ID: 1384145
[TBL] [Abstract][Full Text] [Related]
3. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site.
Greco FA; Johnson DH; Hainsworth JD
Semin Oncol; 1992 Dec; 19(6 Suppl 13):14-8. PubMed ID: 1492223
[TBL] [Abstract][Full Text] [Related]
4. Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site.
Hainsworth JD; Dial TW; Greco FA
Am J Clin Oncol; 1988 Apr; 11(2):138-45. PubMed ID: 2451881
[TBL] [Abstract][Full Text] [Related]
5. The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site.
Hainsworth JD; Johnson DH; Greco FA
Cancer; 1991 Jan; 67(1 Suppl):310-4. PubMed ID: 1984833
[TBL] [Abstract][Full Text] [Related]
6. Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy.
Greco FA; Hainsworth JD
Semin Oncol; 1994 Oct; 21(5 Suppl 12):77-82. PubMed ID: 7992071
[TBL] [Abstract][Full Text] [Related]
7. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site.
Hainsworth JD; Greco FA
Semin Oncol; 1993 Jun; 20(3):279-86. PubMed ID: 8503024
[TBL] [Abstract][Full Text] [Related]
8. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA
J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154
[TBL] [Abstract][Full Text] [Related]
9. The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site.
Greco FA; Hainsworth JD
Semin Oncol; 1989 Aug; 16(4 Suppl 6):116-22. PubMed ID: 2669133
[TBL] [Abstract][Full Text] [Related]
10. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
Lenzi R; Hess KR; Abbruzzese MC; Raber MN; Ordoñez NG; Abbruzzese JL
J Clin Oncol; 1997 May; 15(5):2056-66. PubMed ID: 9164218
[TBL] [Abstract][Full Text] [Related]
11. Poorly differentiated carcinoma of unknown primary site: correlation of light microscopic findings with response to cisplatin-based combination chemotherapy.
Hainsworth JD; Wright EP; Gray GF; Greco FA
J Clin Oncol; 1987 Aug; 5(8):1275-80. PubMed ID: 2442318
[TBL] [Abstract][Full Text] [Related]
12. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome.
Greco FA; Vaughn WK; Hainsworth JD
Ann Intern Med; 1986 Apr; 104(4):547-53. PubMed ID: 3006571
[TBL] [Abstract][Full Text] [Related]
13. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.
van der Gaast A; Verweij J; Planting AS; Hop WC; Stoter G
J Clin Oncol; 1995 Jul; 13(7):1720-5. PubMed ID: 7541451
[TBL] [Abstract][Full Text] [Related]
14. Taxane-based chemotherapy for patients with carcinoma of unknown primary site.
Greco FA; Gray J; Burris HA; Erland JB; Morrissey LH; Hainsworth JD
Cancer J; 2001; 7(3):203-12. PubMed ID: 11419028
[TBL] [Abstract][Full Text] [Related]
15. Management of patients with cancer of unknown primary site.
Hainsworth JD; Greco FA
Oncology (Williston Park); 2000 Apr; 14(4):563-74; discussion 574-6, 578-9. PubMed ID: 10826316
[TBL] [Abstract][Full Text] [Related]
16. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
18. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
Motzer RJ; Rodriguez E; Reuter VE; Bosl GJ; Mazumdar M; Chaganti RS
J Clin Oncol; 1995 Jan; 13(1):274-82. PubMed ID: 7799031
[TBL] [Abstract][Full Text] [Related]
19. Carcinoma of unknown primary: identification of a treatable subset?
van der Gaast A; Verweij J; Henzen-Logmans SC; Rodenburg CJ; Stoter G
Ann Oncol; 1990; 1(2):119-22. PubMed ID: 1706613
[TBL] [Abstract][Full Text] [Related]
20. Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study.
Saghatchian M; Fizazi K; Borel C; Ducreux M; Ruffié P; Le Chevalier T; Théodore C
Ann Oncol; 2001 Apr; 12(4):535-40. PubMed ID: 11398889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
